MobiHealthNews

Patients that got a 'refill' of Pear's reSET-O demonstrated high rates of abstinence

Out of a group of 3,817 people who completed a 12-week prescription of reSET-O, 643 were prescribed a refill of another 12 weeks. For those who completed a total of 24 weeks of treatment, abstinence ...
Business Wire

PursueCare Introduces RESET ® and RESET-O ® —FDA-Authorized Digital Therapeutics for Addiction Treatment

MIDDLETOWN, Conn.--(BUSINESS WIRE)--PursueCare, a leader in virtual addiction treatment, today announced the rollout of RESET ® and RESET-O ®, the only FDA-authorized prescription digital therapeutics ...
Business Wire

Pear Therapeutics Announces Publication of Real-World Data Showing Improved Clinical Outcomes with a Subsequent Prescription of reSET-O® for Patients with Opioid Use Disorder

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Pear Therapeutics, Inc., today announced publication of real-world data evaluating the impact of reSET-O, the first and only FDA-authorized Prescription ...
Nasdaq

Pear Therapeutics Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O®

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today ...
Nasdaq

Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced ...